Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Depreciation & Amortization (CF) (2020 - 2025)

Maxcyte (MXCT) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 0.56% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.3 million, a 0.8% decrease, with the full-year FY2024 number at $4.3 million, up 3.45% from a year prior.
  • Depreciation & Amortization (CF) was $1.1 million for Q3 2025 at Maxcyte, down from $1.1 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.1 million in Q1 2024 to a low of $315900.0 in Q1 2021.
  • A 5-year average of $835573.7 and a median of $1.0 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 120.86% in 2022, then fell 4.08% in 2024.
  • Maxcyte's Depreciation & Amortization (CF) stood at $416500.0 in 2021, then skyrocketed by 120.86% to $919900.0 in 2022, then increased by 19.8% to $1.1 million in 2023, then fell by 4.08% to $1.1 million in 2024, then increased by 1.42% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Depreciation & Amortization (CF) are $1.1 million (Q3 2025), $1.1 million (Q2 2025), and $1.1 million (Q1 2025).